Shareholders meeting

September 28, 2026 To, To, Listing/Compliance Department Listing/Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G-Block, Bandra-Kurla Complex, Mumbai – 400001 Bandra (E), Mumbai – 400051 BSE CODE – 543998 NSE Symbol: VALIANTLAB Dear Sir/ Madam, Sub: Proceedings of the 5th Annual General Meeting of Valiant Laboratories Limited held on Monday, September 28, 2026 at 11:30 AM (IST). Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith summary of the proceedings of the 5th Annual General Meeting of the Company held on Monday, September 28, 2026 at 11:30 A.M. (IST) through Video Conferencing (VC) /Other Audio Visual Means (OAVM). This intimation is also being uploaded on the Company’s website at www.valiantlabs.in Please take note of the above on your record. Thanking you, Yours Faithfully, For Valiant Laboratories Limited Akshay Gangurde Company Secretary & Compliance Officer Encl: As above www.valiantlabs.in | CIN : L24299MH2021PLC365904 Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080. Corporate Office: 701-A, 7th Floor, Tower-B, Embassy 247, L.B.S. Road, Vikhroli (West), Mumbai-400083. T: 022-49712001 / 49717220 /49717221| E: investor@valiantlabs.in Proceedings of the 5th Annual General Meeting of the Company held on Monday, September 28, 2026, at 11:30 A.M. (IST) Present: Mr. Mulesh Savla - Chairman of the Company & Independent Director Mr. Santosh Vora - Managing Director Mr. Paresh Shah - Whole Time Director & Chief Financial Officer Mr. Shantilal Vora - Non – Executive Director Mr. Sandeep Gupta - Non – Executive Director Mr. Ashok Chheda - Independent Director Mr. Akshay Gangurde - Company Secretary In attendance:  Mr. Raman Shah, Statutory Auditor, representing M/s. Raman S. Shah & Co.  Mrs. Monali Bhandari, Secretarial Auditor & Scrutinizer, representing M/s. Mehta and Mehta.  Other management representatives and consultants. ATTENDANCE: 38 members attended the Annual General Meeting (‘AGM’) through Video Conferencing (‘VC’)/Other Audio Visual Means (‘OAVM’). PROCEEDINGS: Mr. Akshay Gangurde, Company Secretary, welcomed the members to the 5th Annual General Meeting of the Company and provided general instructions regarding participation and voting. He informed the Members that Mrs. Sonal Vira, Independent Director of the Company, was unable to attend the Meeting due to her personal exigencies and had sought leave of absence. He further informed that Mrs. Sonal Vira, being the Chairperson of the Nomination and Remuneration Committee, had, in accordance with the Secretarial Standard on General Meetings (SS-2), authorised Mr. Shantilal Vora, a member of the Nomination and Remuneration Committee, to attend the Meeting on her behalf as the representative of the Committee. www.valiantlabs.in | CIN : L24299MH2021PLC365904 Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080. Corporate Office: 701-A, 7th Floor, Tower-B, Embassy 247, L.B.S. Road, Vikhroli (West), Mumbai-400083. T: 022-49712001 / 49717220 /49717221| E: investor@valiantlabs.in Thereafter, Mr. Mulesh Savla, Chairman of the Company, extended a warm welcome to all the members. With the consent of the members present, the Notice of the Meeting and the Auditors’ Report were taken as read. He then requested the Company Secretary to introduce the Board members. The Board of Directors were formally introduced to the shareholders. Members were informed that, in compliance with the provisions of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015, the Company had provided remote e-voting facility prior to the AGM, and e-voting facility during the AGM for all resolutions set out in the Notice. The e-voting shall remain open for 30 minutes’ post conclusion of the meeting. COMPANY OVERVIEW: After the brief introduction, with the permission of the Chairman, Mr. Santosh Vora, Managing Director, was requested to present the performance highlights of the Company. Mr. Santosh Vora, Managing Director, addressed the Members and presented an overview of the Company's performance during FY 2025-26. He briefed the Members on the industry landscape and informed that the Company witnessed improved business performance during the year, supported by stabilising market conditions in the paracetamol API sector. He highlighted the successful completion of the Rights Issue, achievement of a debt-free balance sheet and commencement of commercial operations at the wholly owned subsidiary, Valiant Advanced Sciences Private Limited. He further apprised the Members of the Company's focus on backward integration, operational excellence, quality standards and safety initiatives. He also shared the progress made by Valiant Advanced Sciences Private Limited in commercialising its products and expanding its presence in specialty chemicals. He outlined the Company's key priorities for FY 2026-27, including supporting the subsidiary's growth, strengthening export opportunities, enhancing operational efficiencies and pursuing international quality and regulatory certifications. He concluded by expressing gratitude to the shareholders, employees, customers, business partners, bankers, regulators and other stakeholders for their continued support and confidence in the Company. RESOLUTIONS TRANSACTED: The following items of business, as set out in the Notice, were transacted at the Meeting: Ordinary Business Item No.1 To receive, consider and adopt the Audited Ordinary Resolution Standalone and Consolidated Financial Statements for the financial year ended March www.valiantlabs.in | CIN : L24299MH2021PLC365904 Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080. Corporate Office: 701-A, 7th Floor, Tower-B, Embassy 247, L.B.S. Road, Vikhroli (West), Mumbai-400083. T: 022-49712001 / 49717220 /49717221| E: investor@valiantlabs.in 31, 2026, together with the Reports of the Board of Directors and the Auditors thereon. Item No.2 To appoint a director in place of Mr. Sandeep Ordinary Resolution Gupta (DIN: 09245060), Non-Executive Director, who retires by rotation and who being eligible, offers himself for re- appointment. Special Business Item No.3 Ratification of remuneration to the Cost Ordinary Resolution Auditors for the Financial Year 2026-27. Item No.4 Approval of Material Related Party Ordinary Resolution Transaction(s) with Valiant Organics Limited. Item No.5 Approval of Material Related Party Ordinary Resolution Transaction(s) with Aarti Pharmalabs Limited. Item No.6 Approval of Material Related Party Ordinary Resolution Transaction(s) between Valiant Advanced Sciences Private Limited and Valiant Organics Limited. Item No.7 Approval of Material Related Party Ordinary Resolution Transaction(s) between Valiant Advanced Sciences Private Limited and Aarti Pharmalabs Limited. Item No.8 Approval of Material Related Party Ordinary Resolution Transaction(s) between Valiant Advanced Sciences Private Limited and Alchemie Speciality Chemicals Private Limited. Item No.9 Re-appointment of Mr. Santosh Vora (DIN: Special Resolution 07633923) as Managing Director of the Company for a period of 5 years and to fix his remuneration. Item No.10 Re-appointment of Mrs. Sonal Vira (DIN: Special Resolution 09505883) as an Independent Director for the second term of five consecutive years. Item No.11 Revision in remuneration of Mr. Paresh Shah Special Resolution (DIN: 08291953), Whole-Time Director and Chief Financial Officer. Item No.12 Continuation of Directorship of Mr. Shantilal Special Resolution Vora (DIN: 07633852) as a Non-Executive Non- Independent Director of the Company, upon attaining 75 years of age. Item No.13 Payment of remuneration by way of Special Resolution www.valia [Showing first 8,000 characters — download PDF for full document]